Page 15 - Read Online

Quenelle et al. J Unexplored Med Data 2018;3:7 I http://dx.doi.org/10.20517/2572-8180.2018.02 Page 9 of 10

and neck cancer. Lancet 2000;355:949-55.
2. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck
cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
3. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ,
Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter
KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group.
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
4. Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón
J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. Phase III study comparing cisplatin plus
fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemotherapy in locally advanced head and
neck cancer. J Clin Oncol 2005;23:8636-45.
5. Forastiere AA1, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK.
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell
carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
6. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade
F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus
cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
7. Wiegand S, Zimmermann A, Wilhelm T, Werner JA. Survival after distant metastasis in head and neck cancer. Anticancer Res
2015;35:5499-502.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): head and neck
cancers. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. [Last accessed on 24 Aug 2018]
9. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open label,
uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol
2007;25:2171-7.
10. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem
M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y,
Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene laherparepvec improves durable response rate in patients
with advanced melanoma. J Clin Oncol 2015;33:2780-8.
11. US Food and Drug Administration. Highlights of prescribing information: Keytruda. Available from: https://www.accessdata.fda.gov/
drugsatfda_docs/label/2015/125514s004s006lbl.pdf. [Last accessed on 24 Aug 2018]
12. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow
LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of head and necl
(KEYNOTE-012): an open-label, multicenter, phase 1b trial. Lancet Oncol 2016;17:956-65.
13. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro
K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor activity of
pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from
the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34:3838-45.
14. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli
E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer:
results from a single-arm, phase II study. J Clin Oncol 2017;35:1542-9.
15. Abstract LBA45_PR ‘pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell
carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial’. Ann Oncol 2017; doi: 10.1093/annonc/mdx440.040.
16. Food and Drug Administration. Highlights of prescribing information: nivolumab. Available from: https://www.accessdata.fda.gov/
drugsatfda_docs/label/2017/125554s055lbl.pdf. [Last accessed on 24 Aug 2018]
17. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba
NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856-67.
18. Zandberg D, Algazi A, Jimeno A, Good JS, Fayette J, Bouganim N, Ready N, Clement PM, Goswmi T, Jarkowski A, Armstrong JM,
Asubonteng K, Melillo G, Mesia R. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC):
preliminary results from a single-arm, phase 2 study. Ann Oncol 2017;28:372.
19. Bahleda R, Braiteh FS, Balmanoukian AS, Brana I, Hodi FS, Garbo L, Liu B, Molinero L, O’Hear C, Shen X, Colevas AD. Long-term
safety and clinical outcomes of atezolizumab in head and neck cancer: phase 1a trial results. Ann Oncol 2017;28:373.
20. Mukaigawa T, Hayashi R, Hashimoto K, Ugumori T, Hato N, Fujii S. Programmed death ligand-1 expression is associated with poor
disease free survival in salivary gland carcinomas. J Surg Oncol 2016;114:36-43.
21. Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, Ma Y, Zhao H, Huang Y, Xue C, Huang P, Hu Z, Zhao Y, Zhang L. Co-expression
of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol 2015;32:86.
22. Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani
P, Cheng JD, Hansen AR. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand-1-positive
nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017;35:4050-56.